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Abstract 
Concerns regarding vaccine safety have emerged following reports of potential adverse events 
in both humans and animals. In the present study, alum, alum-containing vaccine and alum 
adjuvant tagged with fluorescent nanodiamonds were used to evaluate i) the persistence time 
at the injection site, ii) translocation of alum from the injection site to lymphoid organs, iii) 
behaviour of adult CD1 mice following intramuscular injection of alum (400 µg Al/kg). 
Results showed for the first time a strikingly delayed systemic translocation of adjuvant 
particles. Alum-induced granuloma remained for a very long time in the injected muscle 
despite progressive shrinkage from day 45 to day 270. Concomitantly, a markedly delayed 
translocation of alum to the draining lymph nodes, major at day 270 endpoint, was observed. 
Translocation to the spleen was similarly delayed (highest number of particles at day 270). In 
contrast to C57BL/6J mice, no brain translocation of alum was observed by day 270 in CD1 
mice. Consistently neither increase of Al cerebral content, nor behavioural changes were 
observed. On the basis of previous reports showing alum neurotoxic effects in CD1 mice, an 
additional experiment was done, and showed early brain translocation at day 45 of alum 
injected subcutaneously at 200 µg Al/kg. This study confirms the striking biopersistence of 
alum. It points out an unexpectedly delayed diffusion of the adjuvant in lymph nodes and 
spleen of CD1 mice, and suggests the importance of mouse strain, route of administration, 
and doses, for futures studies focusing on the potential toxic effects of aluminium-based 
adjuvants. 
 
Keywords: Alum, vaccine-adjuvant, fluorescent-nanodiamonds, delayed-translocation, 
neurotoxicity, CD1 mice. 
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Introduction 
 
Aluminium (Al) is the third most abundant element in the Earth’s crust and it is ubiquitously 
present in our everyday life in a great variety of objects (cooking utensils, food packaging, 
housing materials, pharmaceutical products, cosmetics, etc). Al is found in all body fluids 
(blood, cerebral spinal fluid, interstitial fluid of the brain, lymph, sweat, seminal fluids and 
urine) [1]. Despite the widespread use of Al in our environment leading to this increase of its 
bioavailability, Al has no known biological role [2]. 
Furthermore, it is widely accepted that Al and Al compounds are neurotoxic for animals and 
humans [3,4]. For instance, Al exposure has been implicated in the pathology of several 
neurodegenerative diseases associated with cognitive impairments, as Alzheimer’s disease [5-
7]. The molecular mechanisms by which it causes neuronal damage are not fully understood 
[8], but it is generally accepted that the nervous system is particularly sensitive to oxidant-
mediated damage [9], and that the neurotoxicity of Al is caused by its ability to increase 
oxidative damage in the brain [10]. 
Finally, the bioavailability of Al, its ability to cross the blood-brain barrier, and the relatively 
slow rate of elimination from the brain contribute to progressive accumulation of Al into the 
brain [11-13], and enhance neurotoxicological risk [14]. 
 
Many severe infectious diseases can be prevented by vaccine and some of them have been 
eradicated. Furthermore novel vaccine strategies are now being developed as promising 
therapies to overcome diseases such as cancer. However, though vaccines are commonly and 
safely used, and are generally well tolerated by most people, they occasionally cause adverse 
effects, such as ill-defined conditions usually manifesting as symptoms such as myalgia, 
arthralgia, chronic fatigue and development of autoantibodies [15]. No consensus exists so far 
on a cause-to-effect relationship, but vaccine adjuvants have been suspected to be associated 
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with several inflammatory/neurodegenerative or autoimmune conditions impacting the central 
nervous system such as multiple sclerosis [16], amyotrophic lateral sclerosis [17] and autism 
[6]. A new syndrome has thus been identified by Shoenfeld in 2011, the autoimmune/auto-
inflammatory syndrome induced by adjuvants (ASIA) [18]. 
Several papers from the literature suggest that vaccines containing aluminium adjuvants may 
be insidiously unsafe over the long-term. This is in line with the role of environmental 
aluminium that is continuously suspected to represent a possible co-factor of several chronic 
diseases [19-21,1]. 
 
Among unusual reactions to Aluminium hydroxide (alum) containing vaccines, macrophagic 
myofasciitis (MMF) is an inflammatory lesion described in 1998 [22], and recognized as a 
“distinctive histopathological entity that may be caused by intramuscular injection of Al-
containing vaccines” [23]. 
MMF affects mainly women (>70% of total known cases), and is characterized by highly 
specific myopathological alterations observed in patients suffering from a combination of 
diffuse myalgias, arthralgia, chronic fatigue and cognitive impairment such as alterations 
affecting working memory and attention [22,24-27]. 
Alum-adjuvanted vaccines are usually administered in France through intramuscular injection 
into the deltoid muscle in adults [28]. In MMF patients deltoid muscle biopsies showed 
crystalline cytoplasmic inclusions in macrophages corresponding to alum agglomerates of 
vaccine origin [29]. The constant detection of these agglomerates in MMF assesses the 
unusually long persistence time of alum in affected individuals [30].  
 
Both Al oxyhydroxide and Al hydroxyphosphate are used as vaccine adjuvants [31,32]. 
Indeed, Al has been added to vaccines since the early part of the twentieth century to enhance 
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the primary immunization [33]. The role of Al adjuvants was believed to prolong the retention 
of adsorbed antigens at the injection site, thus reducing the amount of antigen needed per dose 
and the number of required doses [34,35]. However, the “depot” theory has been challenged 
by early ablation of the injected site [36] and mechanisms of alum immunopotentiation only 
begin to be progressively understood [31]. 
Al containing vaccines are commonly used, such as vaccines against tetanus, hepatitis A, 
hepatitis B, human papillomavirus, haemophilus influenzae B, pneumococcal and 
meningococcal infections, and anthrax [37]. FDA regulations limit the Al content of an 
individual vaccinal dose to 0.85 mg of elemental Al [38]. 
 
Previous results have shown that Al particles, as other poorly degradable particles, do not stay 
localized in the injected muscle tissue, but can rather disseminate within phagocyte cells to 
lymph nodes and distant sites including spleen and brain [39]. A previous study of our group 
looked at aluminium translocation after intramuscular injection of alum-containing vaccine in 
C57BL/6J mice. Aluminium was detected in the injected muscle, but also in distant organs 
such as the spleen, a few days after injection, and then in the brain where it was still detected 
one year later. Using surrogate labeled particles containing precipitated alum, a rapid 
phagocytosis of injected particles by muscle monocyte lineage cells and their translocation via 
lymph and blood vessels were confirmed. Particles reached the brain as soon as 3 weeks post-
injection and were shown to accumulate albeit very slowly and in small numbers [39]. 
Recently, we developed a new tool allowing tracing of Al(OH)3 particles in tissues at very 
low levels and over the long-term [40]. This method consists of tagging Al adjuvant itself 
(Alhydrogel
®
) with fluorescent nanodiamonds (fNDs) functionalized with hyperbranched 
polyglycerol (HPG). The complex alum-nanodiamonds (AluDia) had physico-chemical 
properties similar to HBV vaccine [40]. When injected in the tibialis anterior (TA) muscle of 
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C57BL/6J mice, it allowed the monitoring of lymphatic and systemic biodistribution of 
AluDia particles and their presence in brain tissue, 3 weeks after the intramuscular injection. 
 
The potential impact of aluminium adjuvant on the nervous system has been studied in mouse 
models. Aluminium adjuvant, dosed at 100 µg Al/kg and subcutaneously injected in CD1 
mice, induced motor deficits and anxiety increases associated with motor neuron death and 
astrogliosis [17]. Although no motoneuron death was observed when the dose was increased 
3-fold, Shaw and Petrik [41] observed a microglial and astrocytic reactivity in the spinal cord 
of CD1 mice that present with an increase in anxiety, significant impairments in a number of 
motor functions and diminished spatial memory capacity. A neuroinflammatory syndrome has 
been described in sheep after the repetitive administration of Al-containing vaccines [42]. 
Recently, impairment of neurocognitive functions and brain gliosis were reported in a murine 
model of Systemic Lupus Erythematosus-like disease following intramuscular injection of Al 
hydroxide or vaccine against the hepatitis B virus (HBV) (200 µg/mouse) [43]. 
 
Although progressive shrinkage of the local granuloma [44,45] and rapid translocation of 
alum from the injected site to draining lymph nodes (dLNs) and spleen have been repeatedly 
demonstrated [39,40], long-term biodisposition of alum particles trapped in the local 
granuloma remains unexplored. To examine this point we designed a longitudinal study in 
which alum, alum-containing vaccine and alum tagged with fluorescent nanodiamonds were 
used in adult CD1 mice to evaluate i) the persistence time at the injection site, ii) long-term 
translocation of alum from the injection site to lymphoid organs, and iii) behaviour and 
motricity of animals following intramuscular injection of alum. 
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1. Materials and methods 
 
1.1.Dose of exposure 
 
The dose of 400 µg Al/kg was chosen to model a plurivaccination with the HBV ENGERIX
®
 
vaccine. Medical histories of MMF patients revealed that 100% (50/50 patients) of them 
received 1-9 (median 4) doses of an Al-containing vaccine within 10 years prior to their 
diagnosis [29]. A 60-kg woman injected with 1 dose of HBV ENGERIX
®
 vaccine receives 
500 µg of Al, i.e. 8.3 µg Al/kg of body weight. The allometric conversion from human to 
mouse (FDA guidance 5541) gives a final amount of approximately 100 µg Al/kg. 400 µg 
Al/kg was used to mimic a cumulative effect induced by 4 shots. 
 
1.2.Animals 
 
155 female CD1 mice, weighing 25-30 g (7 weeks old), were obtained from Charles Rivers 
Laboratories (France). Upon arrival, the females were housed at 5 per cage. Animals were 
maintained under a 12:12 light cycle, at a constant temperature (22 ± 2°C) and a relative 
humidity of 55 ± 10%. Mice were protected from Al‐containing materials and were given free 
access to food and water. After a 1-week period for acclimatization, mice were separated in 
two experimental series. 
All these experiments on animals were performed in respect with the guidelines provided by 
the European Union (Directive 2010/63/EU) [46]. 
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AluDia translocation series 
After the acclimatization period, 35 8-week old females were separated into 7 experimental 
groups of 5 animals each receiving 3 intra-muscular (im) injections in the left tibialis anterior 
muscle or 3 subcutaneous (sc) injections in the neck, each of 20 µL with a 4-day interval 
between each injection. The 7 groups received AluDia: 200 µg Al/kg, im; 400 µg Al/kg, im; 
200 µg Al/kg, sc; 400 µg Al/kg, sc. The AluDia complex used was identical to the one 
prepared by Eidi et al. [40]. Briefly, the functionalized fluorescent nanodiamonds (fNDs) 
were prepared by milling synthetic HPHT (High Pressure High Temperature) micron powder 
holding nitrogen-vacancy centers (at the origin of permanent fluorescence) created by 
electronic irradiation and annealing [47]. Afterwards, the fNDs are functionalized with hyper 
branched polyglycerol (HPG) synthesized from glycidol (Sigma Aldrich, Saint Quentin 
Fallavier, France) [48] which ensures the colloidal stability of the suspension in buffer and the 
formation of the complex with aluminic particles. The AluDia complex was prepared by 
mixing fND-HPG (1.3 g/L) and Alhydrogel
®
 (10 g/L) suspensions at a ratio of 1:17 v/v and 
followed by a thorough agitation and a few minutes sonication. AluDia suspension was then 
diluted to reach the appropriate concentration in PBS. In the physiological conditions we 
used, AluDia particle size and zeta potential were very similar to those of Alhydrogel
® 
alone 
or HBV vaccine [40].
 
 
Adjuvant/vaccine series 
After the acclimatization period, 120 8-week old females were separated into 3 experimental 
subgroups of 40 animals each receiving 3 intra-muscular injections of 20 µL in TA, with a 4-
day interval between each injection. 
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The 3 groups were: Alhydrogel
® 
group (400 µg Al/kg) (Invivogen, Toulouse, France); 
Vaccine HBV ENGERIX
®
 group (400 µg Al/kg) (Glaxo, Rixensart, Belgium) and a PBS 
control group (Invivogen, Toulouse, France). 
 
Behavioural tests and end point for sacrifice 
Animals were enrolled in a battery of 8 complementary tests two weeks before the endpoint. 
At the end of the behavioural tests (45, 135, 180, 270 days post injection), animals were 
sacrificed with an overdose of pentobarbital (100-150 mg/kg, intra peritoneal injection) and 
samples (TA muscles, dLNs, spleen, and brain) were removed and quickly frozen in 
isopentane, then stored at -80°C until use. Precautions were taken to avoid external 
environmental aluminium contamination of samples. 
Muscle samples of 3 animals from each group were dedicated to the analyses of the 
granuloma size in the injected muscle whereas brain samples of 5 animals were dedicated to 
the measurement of Al concentration. 
 
1.3.Muscle granuloma size at the injection site 
 
The granuloma size was semi-quantitatively assessed on muscle sections stained with 
hematoxylin-eosin in treatment groups that received either the adjuvant Alhydrogel
® 
or the 
HBV vaccine (n=3 muscles per group). Sections were observed with 20X objectives and 
granuloma were assessed according to their size. Four granuloma groups were determined: 
without granuloma (0), small (+), medium (++) and large (+++) granuloma. Then, the 
percentage of each size group was calculated at each time point. 
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1.4.AluDia translocation 
 
AluDia translocation from injection site to target organs (dLNs, spleen, and brain) was 
assessed as previously described by Eidi et al. [40] for 7 AluDia groups: 400 µg Al/kg, im 45, 
135, 180 or 270 days following injection; 200 µg Al/kg, im, 200 µg Al/kg, sc, and  400 µg 
Al/kg, sc 45 days post injection.  
 
Tissue preparation and particle counting 
Serial cryosections of muscle and spleen (20m thick), inguinal lymph node (12m thick) and 
brain (coronal plane, 40m thick) were cut and stored at −20°C until particle counting or 
treatment. Tissue sections were successively deposited on 10 different Superfrost
®
-plus slides 
in order to obtain 10 identical series. The total number of particles per organ was assessed by 
multiplying by 10 the number of particles found in a single series. 
 
Epifluorescence microscopy and microspectrometry 
For fNDs detection, a DPSSL 532 nm (200 mW) laser beam was used as the illumination 
source and was guided to the microscope by a fiber optic. A long pass 600 nm emission filter 
was used to collect only wavelengths higher than 600 nm. Fluorescence images were obtained 
with a Princeton Instruments EMCCD Camera Roleraem–c², with typical exposure times. 
Spectra of the fluorescent spots were acquired by focusing the fluorescent object emission 
from the microscope onto an Acton SP2150i spectrometer (Princeton instruments), and 
detected with a PIXIS–100B–eXcelon CCD camera (Princeton instruments).  
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1.5.Brain Al concentration 
 
Analyses were carried out on 5 brains per group (groups PBS, Alhydrogel
® 
(400 µg Al/kg) 
and HBV vaccine (400 µg Al/kg), 45, 135, 180 or 270 days following injection, according to 
the published method of House et al. [49]. Significant precautions were taken throughout the 
study to minimize contamination. These included storage of all plastic-based laboratory-ware 
in 5% v/v conc. HCl and, before use, rinsing of all such apparatus in several volumes of 
ultrapure water (cond. < 0.067 mS cm-1). Where required, rinsed apparatus was air-dried in a 
dedicated incubator at 37°C. Al concentrations were determined by TH GFAAS in half brains 
dried to a constant weight at 37°C and digested in a microwave (MARS Xpress CEM 
Microwave Technology Ltd) in a mixture of 1 mL 15.8 M HNO3 (Fischer Analytical Grade) 
and 1 mL of 30% w/v H2O2 (BDH Aristar Grade). Digests were clear and colourless or light 
yellow with no visible precipitate or fatty residue. Upon cooling each digest was diluted to a 
total volume of 5 mL with ultrapure water. 
Total Al was measured immediately post digestion using an AAnalyst 600 atomic absorption 
spectrometer with a transversely heated graphite atomizer (THGA) and longitudinal Zeeman-
effect background corrector and an AS-800 autosampler with WinLab32 software (Perkin 
Elmer, UK). Standard THGA pyrolitically-coated graphite tubes with integrated L’Vov 
platform (Perkin Elmer, UK) were used. The Zeeman background corrected peak area of the 
atomic absorption signal was used for the determinations. 
Results were expressed as µg Al/g tissue dry weight. Each determination was the arithmetic 
mean of three injections with a relative standard deviation <10%. 
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1.6.Behavioural and motor testing 
 
A battery of 8 behavioural or physical tests were performed at 45, 135, 180 or 270 days after 
the third injection in groups PBS, Alhydrogel
® 
(400 µg Al/kg) and HBV vaccine (400 µg 
Al/kg). Tests were chosen in order to assess locomotor activity in the open-field [50], level of 
anxiety in the o-maze [51,52], short-term memory in the novel object recognition test [53-56], 
muscular strength in the wire mesh hang [57] and grip strength test [58], locomotor 
coordination in the rotarod test [59], depression in the tail suspension test [60], and pain 
sensitivity in the hot plate test [61]. Detailed procedures can be found in the supplementary 
data. 
 
1.7.Statistical analysis 
 
Tissue Al data were analyzed using a non-parametric Kruskal-Wallis test and a Mann-
Whitney procedure for multiple comparisons. Data from behavioural tests were analyzed 
using a one-way analysis of variance (one-way ANOVA). Post hoc comparisons have been 
performed using the Bonferroni’s test when Anova was significant. 
Significance was set at p<0.05. All statistical analyses were carried out using SPSS 16.0 
software (SPSS INC., Chicago, IL, USA). 
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2. Results 
 
3.1.Muscle granuloma size at the injection site 
 
Serial sections of the injected muscle 45, 135, 180 and 270 days after Alhydrogel
® 
(400 µg 
Al/kg) or HBV vaccine
 
(400 µg Al/kg) injection showed progressive shrinkage of muscle 
granuloma (Table 1). At D45 all animals had granuloma with a majority of sections showing a 
granuloma (93% for Alhydrogel
®
, 67% for HBV vaccine). At D270, in contrast to previous 
time points, one animal was free of granuloma and a majority of overall muscle sections 
showed no granuloma (65% for Alhydrogel
®
, 69% for HBV vaccine) (Table 1). 
 
 
 
3.2.AluDia translocation to dLNs and spleen 
 
The study of translocation of AluDia particles (400 µg Al/kg) from muscle to distant organs 
showed progressive increase of AluDia particles in inguinal dLNs from D45 to D270 after 
injection (Table 2). Indeed, 1145 and 115478 AluDia particles were counted in inguinal dLNs 
at D45 and D270, respectively (Fig. 1). At D270, this 100 fold increase appeared as striking 
accumulation of AluDia in interfollicular areas of dLNs (Table 2 and Fig. 1). In the same 
way, AluDia particles increased by 52 fold in spleen (15 to 785 particles) between D45 and 
D270 (Table 2 and Fig. 1). Of note, particle concentrations were still increasing at the D270 
endpoint in both dLNs and spleen. 
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3.3.Brain translocation of AluDia and behavioural/motricity tests 
 
Surprisingly, no particles were observed in brains at any analyzed times after im injection of 
AluDia (Table 2). Consistently, as assessed by furnace atomic absorption spectrometry, 
animals receiving im injection of Alhydrogel
® 
(400 µg Al/kg) or HBV vaccine (400 µg Al/kg) 
showed no increase of cerebral Al
3+
 level compared to control animals injected with PBS 
(Table 3). Similarly behavioural and motor tests yielded no salient changes in elevated o-
maze, open field, novel object recognition test, wire mesh hang test, grip strength test, rotarod 
test, tail suspension test, and hot plate test (supplementary data). 
Taking into account that neurotoxic effects were previously reported in CD1 mice after sc 
injection of Alhydrogel
® 
at 100 µg Al/kg [17] and 300 µg Al/kg [41], we examined whether 
the route of administration or the dose could influence brain translocation of AluDia. We 
observed that 3 out of 4 CD1 mice injected by the sc route with 200 µg Al/kg showed particle 
incorporation into brain 45 days after injection (Table 4 and Fig. 2). Notably, this was not 
observed at higher dose (400 µg Al/kg) for the sc route, and at any dose for the im route. 
 
4. Discussion 
 
This longitudinal study showed that alum (Alhydrogel
® 
or HBV vaccine) injected into muscle 
constantly induces a granuloma similar to MMF that shrinks with time with marked clearance 
of granulomatous lesions observed from D180 to D270. This is similar to what was 
previously observed with the AluDia complex [40]. Granuloma shrinkage in muscle was 
associated with concurrent replenishment of inguinal dLNs (100 fold increase of AluDia 
particles from D45 to D270). Similar translocation of alum from muscle to dLNs was 
previously observed at much earlier time points in C57BL/6J mice [39]. We assume that two 
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waves of lymphatic translocation may occur after im injection of alum: an early one peaking 
at D4 [39], and a markedly delayed one associated with muscle granuloma shrinkage 
observed in the present study thanks to a long-term evaluation not performed in previous 
studies. We assume that this delayed lymphatic draining flux is the normal way of clearance 
for alum trapped in the post-vaccinal granuloma. Similarly to translocation to dLNs, we 
observed markedly delayed AluDia translocation to spleen, with a maximum number of 
particles being detected in this organ at D270. Alum translocation from muscle to spleen was 
previously shown to assess particle exit from lymphatic pathways to blood stream [39]. Since 
spleen was previously shown to incorporate a first peak of particles at D7 post im injection in 
C57BL/6J mice [40], the present study suggests a delayed second wave of adjuvant 
translocation to spleen in line with that observed in dLNs.  
The present study confirms that alum is extremely biopersistent [29,37] and that alum 
biopersistence can be observed in both the injected muscle and distant organs, including dLNs 
and spleen. Regarding the strong immunostimulatory effects of alum and the unrequired depot 
formation for its adjuvant activity [36], long-term biopersistence of alum in lymphoid organs 
is clearly undesirable, and may cast doubts on the exact level of long-term safety of alum-
adjuvanted vaccines [37]. 
 
The lack of brain translocation alum after im injection of 400 µg Al/kg was puzzling. 
Notably, neither elevated Al concentration in brain nor neurobehavioural changes were 
observed in these experimental conditions, ruling out significant translocation of soluble Al to 
brain in the absence of physical incorporation of alum particles, and the induction of 
neurobehavioral effects by chronic peripheral immune activation linked to persistence of alum 
within immune cells [35]. 
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It is not excluded that the observed difference in the biodisposition of alum in C57BL/6J and 
CD1 mice, including diffusion kinetics and the occurrence of brain translocation, may in part 
reflect differences in the genetic background of the two strains [62]. We previously 
demonstrated that the size of the alum-induced granuloma in rats is dramatically influenced 
by their genetic background, the granuloma being much smaller in Lewis rats with Th1 biased 
immune responses compared to Sprague–Dawley rats with balanced Th1/Th2 immunity [45]. 
The C57BL/6 mouse strain is known to exhibit a Th1-prone, pro-inflammatory type response 
to injury [63,64]. To our knowledge, the T helper immunity status of CD1 mice is not known.  
Interestingly, C57BL/6 mice produce more MCP-1/CCL2 than other strains [64], and this 
major inflammatory monocyte chemoattractant is crucially involved in both systemic 
biodistribution and neurodelivery of Al particles captured by monocyte-lineage cells [39]. 
Notably, increased circulating MCP-1/CCL2 is the sole identified biomarker in myalgic 
encephalomyelitis patients with MMF [65]. Moreover, human MMF is mainly observed in 
middle aged or elderly individuals, a time when MCP-1/CCL2 production increases and 
immuno-senescence occurs [66]. Clarification of the influence of mouse strains Th1 and Th2-
biased immune responses in AluDia brain translocation clearly deserves future studies. 
In previous published studies, motor and behavioural impairments were observed following sc 
(behind the neck) Alhydrogel
®
 injection to CD1 mice with doses of 100 and 300 µg Al/kg 
[17,41]. These effects were associated with Al deposits in the central nervous system (spinal 
cord) assessed by Morin stain. To examine if the route of exposure may represent an 
important factor for alum toxicity, a nested study was conducted herein, showing that alum 
particles may penetrate the brain at D45 after the sc (and not im) injection, performed at the 
dose of 200 µg Al/kg (and not at the dose of 400 µg Al/kg). A higher rate of brain 
translocation after sc injection may be explained by a much higher density of dendritic cells 
with high migrating properties, in the skin compared to muscle. The fact that half dose 
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resulted in brain translocation, which was not observed at higher dose, is reminiscent of the 
non monotonic dose/response curves previously observed with environmental toxins, 
including particulate compounds [67]. In another study, we similarly observed 
neurobehavioural changes at 200 but not 400 µg Al/kg (Crépeaux et al., manuscript in 
preparation). The exact significance of such observations is unknown, but one may speculate 
that huge quantities of alum injected in the tissue may induce blockade of critical macrophage 
functions such as migration and xeno/autophagic disposition of particles, as previously 
reported for infectious particles [37]. 
 
5. Conclusion 
 
We observed a strikingly delayed, previously unknown, systemic translocation of alum 
particles injected into muscle, with conspicuous alum accumulations in the lymphatic system 
and spleen 9 months after injection. In addition to the crucial ‘t” factor, our results strongly 
suggest the influence of the mouse strain, the dose and the route of administration on alum 
biodisposition. All these parameters should be taken into account in the design of future alum 
toxicological studies. 
 
List of abbreviations 
AluDia: aluminium-nanodiamonds complex  
ASIA: autoimmune/auto-inflammatory syndrome induced by adjuvants  
 dLNs: draining lymph nodes 
FDA: food and drug administration 
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Fig. 1. AluDia accumulation in inguinal dLNs (a,b, f,g) and spleen (c,d,h,i) following AluDia im injection in tibialis anterior muscle (400 µg 
Al/kg) at D45 (a-e) and at D270 (f-j). 
a, c, f, h: The red specific fluorescence of AluDia excited by a 532 nm laser source. 
b, d, g, i: phase contrast. 
e and j: AluDia luminescence spectrum with a specific peak at 700 nm.  
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Fig. 2. AluDia in brain (animal 1: a, b, c; animal 2: d, e, f) following AluDia sc injection (200 µg Al/kg) at D45. 
a and d: The red specific fluorescence of AluDia excited by a 532 nm laser source. 
b and e: phase contrast. 
c and f: AluDia luminescence spectrum with a specific peak at 700 nm  
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Table 1 
A semi-quantitative study of the progressive decrease of granuloma size in injected muscle 
with Alhydrogel or HBV vaccine.  
 
According to their size, observed granulomas were divided to four types: without granuloma 
(0), small (+), medium (++) and large (+++) granuloma. Then, percentage of each size in 
observed muscles was calculated, for n = 3 animals per group.  
Group Days
No 
granuloma
(0)
Small 
granuloma 
(+)
Medium 
granuloma
(++)
Large 
granuloma
(+++)
Total 
granuloma
Alhydrogel® D45 7% 14% 46% 32% 93%
400 µg Al/kg, im D135 35% 21% 18% 26% 65%
D180 24% 28% 43% 5% 76%
D270 65% 18% 10% 6% 35%
HBV vaccine® D45 32% 42% 22% 4% 67%
400 µg Al/kg, im D135 21% 35% 31% 13% 79%
D180 35% 41% 25% 0% 65%
D270 69% 25% 6% 0% 31%
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Table 2 
A qualitative study of the translocation of AluDia particles following intramuscular injections 
at the dose of 400 µg Al/kg, 45, 135, 180 or 270 days after injections. 
 
Results are expressed as mean ± S.D. of n = 3 mice/group per organ and per time point. 
Ing dLNs, Inguinal draining lymph nodes.  
Brain
mean ± sd mean ± sd mean
D45 1145 ± 87 15 ± 3 0
D135 3820 ± 123 55 ± 12 0
D180 7372 ± 194 177 ± 32 0
D270 115478 ± 377 785 ± 61 0
AluDia Ing DLNs Spleen
Particle counts
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Table 3 
Aluminum cerebral concentration measured by furnace atomic absorption spectrometry (µg/g 
of dry weight). 
 
Results are expressed as median and quartiles (in brackets) of n = 5 brains/group. Non 
parametric Kruskal-Wallis test followed by a Mann-Whitney procedure was used for multiple 
comparisons. 
* p < 0.05, statistical significant difference from controls.  
Cerebral Al 
concentration
Control
Alhydrogel® goup
400 µg Al/kg, im
HBV vaccine group
400 µg Al/kg, im
Kruskal-
Wallis test
D45 0.54095 0.57335 0.90625 n.s.
(0.3250 - 1.4837) (0.0234 - 8.8778) (0.6104 - 1.3623)
D135 0.02485 0.4317 0.6843 n.s.
(0.0179 - 0.1877) (0.0200 - 33.3432) (0.1214 - 1.2061)
D180 0.0956 0.0143 0.0451 n.s.
(0.0174 - 0.8776) (0.0133 - 0.3540) (0.0158 - 0.6317)
D270 1.0534 0.01495 * 0.0141 * p < 0.05
(0.3975 - 2.8053) (0.0123 - 0.1859) (0.0122 - 0.0206)
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Table 4 
A qualitative study of the translocation of AluDia particles following intramuscular or 
subcutaneous injections at the doses of 200 or 400 µg/kg, 45 days after injections. 
 
Results are expressed as mean ± S.D. of n = 4 mice/group per organ and per time point. 
Im, intramuscular; sc, subcutaneous. 
  
im 200 µg Al/kg im 400 µg Al/kg sc 200 µg Al/kg sc 400 µg Al/kg
Brain 0 0 15±7 0
AluDia
Particle counts
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Highlights 
- Vaccine safety is a key question due to reported adverse events in humans & animals 
- Results showed a highly delayed systemic translocation of adjuvant particles 
- This study suggests the importance of mouse strain, route of exposure & doses 
- This study confirms the striking biopersistence of alum 
